As of 14 Oct 2026, Stipple Bio has raised $100M across 1 verified round on record; latest: $100 million Series A, announced 6 Apr 2026.
Stipple Bio develops targeted oncology therapies through precision mapping of tumor-specific epitopes for cancer treatment.
1 source
The accessible source does not name any investors, valuation, financing total, or headquarters.; not on the page it cites, so not applied: date
Published by hand (bizjournals.com): "CEO Jeff Landau said the $100 million Series A round was so heavily oversubscribed the company had to turn away multiple venture firms.": biggest-rounds completeness (K): the row's own page states the round
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2026-04-06 | not stated | No recent discussion |
1 source [ VERIFIED ] read against 1 source The accessible source does not name any investors, valuation, financing total, or headquarters.; not on the page it cites, so not applied: date Published by hand (bizjournals.com): "CEO Jeff Landau said the $100 million Series A round was so heavily oversubscribed the company had to turn away multiple venture firms.": biggest-rounds completeness (K): the row's own page states the round | ||||
None named.